• Explore /
  • Poster
  • / KEYNOTE-564: A phase 3, randomized, double blind, trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma.

KEYNOTE-564: A phase 3, randomized, double blind, trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma.

Abstract Poster

Authors

Toni Choueiri

Toni K. Choueiri

Dana-Farber Cancer Institute, Boston, MA

Toni K. Choueiri , David I. Quinn , Tian Zhang , Howard Gurney , Gurjyot K. Doshi , Patrick Wayne Cobb , Francis Parnis , Jae-Lyun Lee , Se Hoon Park , Andrey Semenov , Wayne Yen-Hwa Chang , Shuyan M. Wan , Christian Heinrich Poehlein , Thomas Powles

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary (Nonprostate) Cancer

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Kidney Cancer

Clinical Trial Registration Number

NCT03142334

Citation

J Clin Oncol 36, 2018 (suppl; abstr TPS4599)

DOI

10.1200/JCO.2018.36.15_suppl.TPS4599

Abstract #

TPS4599

Poster Bd #

418b

Abstract Disclosures

Similar Posters

First Author: David I. Quinn

First Author: Minal A. Barve

First Author: Toni K. Choueiri

First Author: Alain Patrick Algazi